Developmental Therapeutics Program

One Dose Mean Graph

NSC: 771826 / 1	Conc: 1.00E-5 Molar	Test Date: Jan 14, 2013
Experiment ID: 1301OS10		Report Date: Mar 25, 2013

Panel/Cell Line	Growth Percent
Leukemia	
CCRF-CEM	86.98
HL-60(TB)	90.90
K-562	84.37
MOLT-4	81.99
RPMI-8226	90.93
SR	87.08
Non-Small Cell Lung Cancer	
A549/ATCC	95.65
HOP-62	94.94
HOP-92	75.74
NCI-H226	100.82
NCI-H23	95.77
NCI-H322M	88.76
NCI-H460	103.32
NCI-H522	84.37
Colon Cancer	
COLO 205	108.33
HCC-2998	103.36
HCT-116	91.29
HCT-15	95.82
HT29	89.92
KM12	95.59
SW-620	101.16
CNS Cancer	
SF-268	106.43
SF-295	93.59
SF-539	99.54
SNB-19	102.53
SNB-75	98.72
U251	97.65
Melanoma	
LOX IMVI	99.10
MALME-3M	85.19
M14	95.10
MDA-MB-435	102.68
SK-MEL-2	76.38
SK-MEL-28	111.98
SK-MEL-5	100.74
UACC-257	95.36
UACC-62	95.06
Ovarian Cancer	
IGROV1	104.07
OVCAR-3	109.33
OVCAR-4	103.82
OVCAR-5	95.30
OVCAR-8	98.47
NCI/ADR-RES	98.05
SK-OV-3	110.22
Renal Cancer	
786-0	83.87
A498	88.52
ACHN	98.98
CAKI-1	94.61
RXF 393	113.12
SN12C	97.73
TK-10	86.10
UO-31	79.87
Prostate Cancer	
PC-3	93.85
DU-145	110.51
Breast Cancer	
MCF7	98.93
MDA-MB-231/ATCC	113.54
HS 578T	103.10
BT-549	86.59
T-47D	85.76
MDA-MB-468	93.11
Mean	95.84
Delta	20.10
Range	37.80

Mean Growth Percent - Growth Percent